ANGPTL4 in Metabolic and Cardiovascular Disease

Trends Mol Med. 2019 Aug;25(8):723-734. doi: 10.1016/j.molmed.2019.05.010. Epub 2019 Jun 21.

Abstract

Alterations in circulating lipids and ectopic lipid deposition impact on the risk of developing cardiovascular and metabolic diseases. Lipoprotein lipase (LPL) hydrolyzes fatty acids (FAs) from triglyceride (TAG)-rich lipoproteins including very low density lipoproteins (VLDLs) and chylomicrons, and regulates their distribution to peripheral tissues. Angiopoietin-like 4 (ANGPTL4) mediates the inhibition of LPL activity under different circumstances. Accumulating evidence associates ANGPTL4 directly with the risk of atherosclerosis and type 2 diabetes (T2D). This review focuses on recent findings on the role of ANGPTL4 in metabolic and cardiovascular diseases. We highlight human and murine studies that explore ANGPTL4 functions in different tissues and how these effect disease development through possible autocrine and paracrine forms of regulation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiopoietin-Like Protein 4 / chemistry
  • Angiopoietin-Like Protein 4 / genetics*
  • Angiopoietin-Like Protein 4 / metabolism
  • Animals
  • Biomarkers
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / metabolism*
  • Cardiovascular Diseases / pathology
  • Diabetes Mellitus / etiology
  • Diabetes Mellitus / metabolism
  • Disease Susceptibility*
  • Energy Metabolism*
  • Gene Expression
  • Humans
  • Lipid Metabolism / drug effects
  • Metabolic Diseases / genetics
  • Metabolic Diseases / metabolism
  • Molecular Targeted Therapy
  • Organ Specificity
  • Structure-Activity Relationship

Substances

  • ANGPTL4 protein, human
  • Angiopoietin-Like Protein 4
  • Biomarkers